Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05014204 · ClinicalTrials.gov registry record · NA
Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes
A NA study, sponsored by Endogenex.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT05014204: Completed NA study, sponsored by Endogenex.
NCT05014204 is a NA study that has completed, run by Endogenex. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05014204, a NA study, has completed, sponsored by Endogenex.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a multi-center, open-label study to assess the feasibility and preliminary safety of the Endogenex Device for endoscopic duodenal mucosal regeneration in patients with type 2 Diabetes inadequately controlled on 2-3 non-insulin glucose-lowering medications.
Primary Outcome
Number of participants experiencing device- or procedure-related serious adverse events (SAE)
Interventions
- DEVICE The Endogenex Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-10-29 |
| Est. Completion | 2025-05-29 |
| Phase | NA |
What the finished NCT05014204 record still lists
NCT05014204 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which The Endogenex Device is the first listed.
NCT05014204 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05014204 about?
NCT05014204 is a clinical study titled "Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes". This is a multi-center, open-label study to assess the feasibility and preliminary safety of the Endogenex Device for endoscopic duodenal mucosal regeneration in patients with type 2 Diabetes inadequately controlled on 2-3 non-insulin glucose-lowering medications.
What is the current status of trial NCT05014204?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2021-10-29. Estimated completion is 2025-05-29.
What interventions are being tested in trial NCT05014204?
The interventions under investigation include: The Endogenex Device (DEVICE).
Who is sponsoring clinical trial NCT05014204?
This trial is sponsored by Endogenex, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05014204's enrollment target sits among peer trials
20 1768th of 2000 higher than 140 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI